Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (111-120 of 426) with videos related to

Pageof 43
Sort By:
Frontiers in Oncology|March 6, 2023
Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinomaElla Barkan, Camillo Porta, Simona Rabinovici-Cohen, et al.
Critical Reviews in Oncology/Hematology|December 21, 2025
A daily clinical practice decision-making overview for the present metastatic renal cell carcinoma (mRCC) management landscapeSergio Bracarda, Fabio Calabrò, Ugo De Giorgi, et al.
Tumori|October 28, 2009
Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysisElisa Ferraris, Pamela Di Cesare, Angioletta Lasagna, et al.
Lung Cancer (Amsterdam, Netherlands)|October 26, 2002
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?Camillo Porta, Vittoria Rizzo, Matteo Zimatore, et al.
Nature Reviews. Nephrology|March 28, 2019
The adjuvant treatment of kidney cancer: a multidisciplinary outlookCamillo Porta, Laura Cosmai, Bradley C Leibovich, et al.
American Journal of Translational Research|September 20, 2021
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitorsGaetano Pezzicoli, Giacomo Triggiano, Maria Chiara Sergi, et al.
Tumori|February 8, 2014
Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytesSimona Secondino, Ilaria Turin, Enrica Montini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenograftsPietro Bertino, Federica Piccardi, Camillo Porta, et al.
Therapeutic Advances in Urology|July 2, 2021
Second-line treatment in renal cell carcinoma: clinical experience and decision makingValentina Guadalupi, Giacomo Cartenì, Roberto Iacovelli, et al.
European Urology Focus|May 4, 2025
Re: Justine Panian, Caiwei Zhong, Sharon H. Choi, et al. Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.11.011Viktor Grünwald, Thomas Powles, Thomas E Hutson, et al.
Pageof 43

Showing results (111-120 of 426) with videos related to

Sort By:
Pageof 43
Frontiers in Oncology|March 6, 2023
Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinomaElla Barkan, Camillo Porta, Simona Rabinovici-Cohen, et al.
Critical Reviews in Oncology/Hematology|December 21, 2025
A daily clinical practice decision-making overview for the present metastatic renal cell carcinoma (mRCC) management landscapeSergio Bracarda, Fabio Calabrò, Ugo De Giorgi, et al.
Tumori|October 28, 2009
Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysisElisa Ferraris, Pamela Di Cesare, Angioletta Lasagna, et al.
Lung Cancer (Amsterdam, Netherlands)|October 26, 2002
Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?Camillo Porta, Vittoria Rizzo, Matteo Zimatore, et al.
Nature Reviews. Nephrology|March 28, 2019
The adjuvant treatment of kidney cancer: a multidisciplinary outlookCamillo Porta, Laura Cosmai, Bradley C Leibovich, et al.
American Journal of Translational Research|September 20, 2021
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitorsGaetano Pezzicoli, Giacomo Triggiano, Maria Chiara Sergi, et al.
Tumori|February 8, 2014
Case report: long-lasting response in a patient with metastatic renal cell cancer receiving antitumor cytotoxic T lymphocytesSimona Secondino, Ilaria Turin, Enrica Montini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenograftsPietro Bertino, Federica Piccardi, Camillo Porta, et al.
Therapeutic Advances in Urology|July 2, 2021
Second-line treatment in renal cell carcinoma: clinical experience and decision makingValentina Guadalupi, Giacomo Cartenì, Roberto Iacovelli, et al.
European Urology Focus|May 4, 2025
Re: Justine Panian, Caiwei Zhong, Sharon H. Choi, et al. Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2024.11.011Viktor Grünwald, Thomas Powles, Thomas E Hutson, et al.
Pageof 43